Test Price
2,800 AED✅ Home Collection Available
ALAS2 Gene Protoporphyria, Erythropoietic, X-linked Genetic Test in UAE | 2800 AED | DHA Approved
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post-test result interpretation with a board-certified clinical geneticist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This definitive Next-Generation Sequencing (NGS) assay analyses the entire coding region and splice sites of the ALAS2 gene to diagnose X-linked erythropoietic protoporphyria (XLEPP) and X-linked sideroblastic anemia (XLSA). The test provides precise molecular characterization of pathogenic variants, enabling accurate diagnosis, carrier detection, and informed family counselling.
| Feature | Our Test (NGS – ALAS2 Complete) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Analytical Sensitivity | >99.9% for single nucleotide variants and indels | ~95% due to limited coverage of flanking regions |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Regulatory Compliance | DHA/MOHAP approved, ISO 15189, CLIA certified | Often research-grade, may lack clinical validation |
Physician Insight & Safety Protocols
"Early and precise genetic diagnosis of ALAS2-related disorders can transform clinical management for affected families. This NGS-based test provides comprehensive coverage of the gene, but results must always be correlated with clinical presentation and family history. I advise all patients to discuss findings with their specialist to ensure appropriate follow-up and management."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Note on Clinical Management
⚠️ Medication Safety
Patients are advised to continue all prescribed treatments unless explicitly directed otherwise by their managing physician. Genetic test results are intended to inform clinical decision-making and should not be used as a sole basis for altering therapeutic regimens. Always consult your healthcare provider before making any changes to your medication.
Exclusion Criteria & Emergency Red Flags
- Recent blood transfusion within 4 weeks (may cause donor DNA interference).
- Inability to provide a blood sample or DNA source due to severe thrombocytopenia or ongoing anticoagulant therapy that cannot be paused.
- Seek immediate emergency care if you experience: acute severe photosensitivity with blistering, dark urine, abdominal pain, or altered consciousness — these may indicate acute hepatic porphyria exacerbation.
Patient FAQ & Clinical Guidance
1. What conditions does the ALAS2 NGS test detect?
This test identifies pathogenic variants in the ALAS2 gene causing X-linked erythropoietic protoporphyria (XLEPP) and X-linked sideroblastic anemia (XLSA), providing a molecular diagnosis for photosensitivity and anemia disorders. Additional findings may include carrier status for at-risk female relatives. The report includes variant classification per ACMG guidelines.
2. How should I prepare for the test?
A mandatory pre-test genetic counseling session is required to draw a pedigree and obtain informed consent, ensuring accurate clinical correlation and family risk assessment. A blood sample (EDTA tube) or DNA FTA card will be collected by a licensed phlebotomist. No fasting is necessary. Provide complete medical and family history to the genetic counsellor.
3. What is the cost and turnaround time?
The total price is 2800 AED, inclusive of home collection, analysis, and a post-test teleconsultation — results are delivered within 3 to 4 weeks via a secure online portal. Insurance may cover the cost; we provide direct billing assistance. No hidden fees apply.
UAE Regulatory & Data Privacy Adherence
Data Protection & Healthcare Compliance
- All genetic data is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Laboratory operations are conducted under DHA Facility License Number: 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | ALAS2 Gene Sequencing – X-linked Erythropoietic Protoporphyria & Sideroblastic Anemia (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or DNA Sample (FTA card or extracted DNA) |
| Methodology Used | Next-Generation Sequencing (NGS) – complete coding region and splice sites of ALAS2 |
| ICD-10-CM Code | E80.0, D64.0 |
| LOINC Code | 21663-2 |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians